19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Patient sample and mouse studies suggest gene editing of CD40L cDNA in autologous hematopoietic stem cells (HSCs) could help treat X-linked hyper-IgM syndrome (XHIM), which is caused by CD40L mutations. In patient-derived T cells,...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
02:28 , Mar 9, 2018 |  BC Innovations  |  Product R&D

Chips for tox

After several years’ pushing from FDA, NIH and DARPA for more predictive preclinical tox tests, organ-on-a-chip companies are close to demonstrating their models can detect signals missed in animals. While replacing animals is nowhere in...
17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

MedImmune spins out autoimmune play Viela

The MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of MedImmune’s Respiratory, Inflammation & Autoimmunity...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
11:06 , Sep 8, 2017 |  BioCentury  |  Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...
01:44 , Feb 25, 2017 |  BioCentury  |  Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Agonistic families

TNF superfamily receptors and their ligands have long been recognized as clinically relevant therapeutic targets for cancer, and dozens of companies are using different therapeutic modalities to target the proteins. Apogenix AG is one of...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Mologen cancer, infectious news

Mologen will reduce headcount by 17 (26%) to 49 and focus on developing lead product lefitolimod ( MGN1703), a toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) technology. The...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...